Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (DE:BRM)
XETRA:BRM
BRM Stock Chart & Stats
€52.85
-€0.23(-0.42%)
At close: 4:00 PM EST
€52.85
-€0.23(-0.42%)
Day’s Range― - ―
52-Week Range€36.60 - €58.20
Previous CloseN/A
Volume2.10K
Average Volume (3M)2.66K
Market Cap
€107.15B
Enterprise Value€162.04B
Total Cash (Recent Filing)€10.67B
Total Debt (Recent Filing)€47.14B
Price to Earnings (P/E)17.2
Beta0.47
Next Earnings
Apr 30, 2026EPS Estimate
1.24Next Dividend Ex-DateN/A
Dividend Yield5.01%
Share Statistics
EPS (TTM)1.08
Shares Outstanding2,036,473,800
10 Day Avg. Volume2,243
30 Day Avg. Volume2,659
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€52.93Price Target Upside0.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)5.28
Revenue Forecast (FY)€39.44B
Bulls Say, Bears Say
Bulls Say
Growth Portfolio Commercial MomentumStronger-than-expected sales for growth-stage medicines such as Reblozyl, Breyanzi, and Camzyos helped drive revenue and earnings beats, supporting confidence in the company's ability to offset declines in legacy products.
Milvexian Program DeriskingFavorable late-stage results from a competitor's anticoagulant provide a positive clinical readthrough that reduces uncertainty around milvexian's prospects and increases confidence ahead of its pivotal data.
Pricing And ReimbursementNew U.S. pricing rules and a one-time pricing adjustment reduced rebate and penalty liabilities for Eliquis, improving revenue predictability and providing additional cash flow to support growth-stage launches.
Bears Say
Accelerated Approval Conversion RiskReliance on minimal residual disease for accelerated approval means conversion to full approval will require confirmatory progression-free survival or overall survival benefits, creating regulatory uncertainty until those outcomes are achieved.
Concentrated Pipeline Readout RiskA concentration of important registrational readouts across multiple late-stage programs increases clinical and regulatory risk and could cause pronounced swings in investor expectations if key results disappoint.
Iberdomide Safety And TolerabilitySelection of a low iberdomide dose and prior observations of neutropenia raise safety and tolerability concerns that could limit dosing flexibility and commercial adoption.
Bristol-Myers Squibb News
BRM FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €36.60 and its highest was €58.20 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is €107.15B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 30, 2026 which is in 57 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 05, 2026. The company reported €1.083 earnings per share for the quarter, beating the consensus estimate of €1.054 by €0.029.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of €0.528 which represents an annual dividend yield of 5.01%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.24.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,036,473,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.083 in its last earnings report, beating expectations of €1.054. Following the earnings report the stock price went up 4.011%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in DE:BRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€52.93 (0.15% Upside)
€52.93 (0.15% Upside)
Blogger Sentiment
Bullish
DE:BRM Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.84%
12-Months-Change
Fundamentals
Return on Equity
40.53%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BRM Company Deck
BRM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all DE:BRM earnings summariesBRM Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BRM Stock 12 Month Forecast
Average Price Target
€52.93
▲(0.15% Upside)
Technical Analysis
Options Prices
Currently, No data available
---